PMC:7253482 / 74-402
Annnotations
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 25 | 59-112 | Species | denotes | Middle East respiratory syndrome (MERS) coronaviruses | Tax:1335626 |
| 26 | 114-118 | Species | denotes | CoVs | Tax:11118 |
| 27 | 317-328 | Species | denotes | Coronavirus | Tax:11118 |
| 33 | 293-298 | Gene | denotes | spike | Gene:43740568 |
| 39 | 14-47 | Disease | denotes | Severe acute respiratory syndrome | MESH:D045169 |
| 40 | 49-53 | Disease | denotes | SARS | MESH:D045169 |
| 41 | 124-132 | Disease | denotes | zoonotic | MESH:D015047 |
LitCovid-PD-FMA-UBERON
| Id | Subject | Object | Predicate | Lexical cue | fma_id |
|---|---|---|---|---|---|
| T1 | 303-315 | Body_part | denotes | glycoprotein | http://purl.org/sig/ont/fma/fma62925 |
LitCovid-PD-MONDO
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T1 | 14-47 | Disease | denotes | Severe acute respiratory syndrome | http://purl.obolibrary.org/obo/MONDO_0005091 |
| T2 | 49-53 | Disease | denotes | SARS | http://purl.obolibrary.org/obo/MONDO_0005091 |
LitCovid-PD-CLO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 212-219 | http://purl.obolibrary.org/obo/CLO_0009985 | denotes | focuses |
LitCovid-PD-CHEBI
| Id | Subject | Object | Predicate | Lexical cue | chebi_id |
|---|---|---|---|---|---|
| T1 | 303-315 | Chemical | denotes | glycoprotein | http://purl.obolibrary.org/obo/CHEBI_17089 |
LitCovid-sample-PD-IDO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 133-142 | http://purl.obolibrary.org/obo/IDO_0000528 | denotes | pathogens |
| T2 | 264-287 | http://purl.obolibrary.org/obo/GO_0006959 | denotes | humoral immune response |
| T3 | 272-287 | http://purl.obolibrary.org/obo/GO_0006955 | denotes | immune response |
LitCovid-sample-Enju
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T8 | 5-13 | NN | denotes | Abstract |
| T9 | 14-20 | JJ | denotes | Severe |
| T10 | 21-26 | JJ | denotes | acute |
| T11 | 27-38 | JJ | denotes | respiratory |
| T12 | 39-47 | NN | denotes | syndrome |
| T13 | 48-49 | -LRB- | denotes | ( |
| T14 | 49-53 | NN | denotes | SARS |
| T15 | 53-54 | -RRB- | denotes | ) |
| T16 | 55-58 | CC | denotes | and |
| T17 | 59-65 | NNP | denotes | Middle |
| T18 | 66-70 | NNP | denotes | East |
| T19 | 71-82 | JJ | denotes | respiratory |
| T20 | 83-91 | NN | denotes | syndrome |
| T21 | 92-93 | -LRB- | denotes | ( |
| T22 | 93-97 | NNS | denotes | MERS |
| T23 | 97-98 | -RRB- | denotes | ) |
| T24 | 99-112 | NNS | denotes | coronaviruses |
| T25 | 113-114 | -LRB- | denotes | ( |
| T26 | 114-118 | NNS | denotes | CoVs |
| T27 | 118-119 | -RRB- | denotes | ) |
| T28 | 120-123 | VBP | denotes | are |
| T29 | 124-132 | JJ | denotes | zoonotic |
| T30 | 133-142 | NNS | denotes | pathogens |
| T31 | 143-147 | IN | denotes | with |
| T32 | 148-152 | JJ | denotes | high |
| T33 | 153-161 | NN | denotes | fatality |
| T34 | 162-167 | NNS | denotes | rates |
| T35 | 168-171 | CC | denotes | and |
| T36 | 172-180 | JJ | denotes | pandemic |
| T37 | 181-190 | NN | denotes | potential |
| T38 | 192-199 | NN | denotes | Vaccine |
| T39 | 200-211 | NN | denotes | development |
| T40 | 212-219 | VBZ | denotes | focuses |
| T41 | 220-222 | IN | denotes | on |
| T42 | 223-226 | DT | denotes | the |
| T43 | 227-236 | JJ | denotes | principal |
| T44 | 237-243 | NN | denotes | target |
| T45 | 244-246 | IN | denotes | of |
| T46 | 247-250 | DT | denotes | the |
| T47 | 251-263 | VBG | denotes | neutralizing |
| T48 | 264-271 | JJ | denotes | humoral |
| T49 | 272-278 | JJ | denotes | immune |
| T50 | 279-287 | NN | denotes | response |
| T51 | 287-288 | -COMMA- | denotes | , |
| T52 | 289-292 | DT | denotes | the |
| T53 | 293-298 | NN | denotes | spike |
| T54 | 299-300 | -LRB- | denotes | ( |
| T55 | 300-301 | NN | denotes | S |
| T56 | 301-302 | -RRB- | denotes | ) |
| T57 | 303-315 | NN | denotes | glycoprotein |
| T58 | 317-328 | NN | denotes | Coronavirus |
| R7 | T12 | T9 | arg1Of | syndrome,Severe |
| R8 | T12 | T10 | arg1Of | syndrome,acute |
| R9 | T12 | T11 | arg1Of | syndrome,respiratory |
| R10 | T12 | T13 | arg1Of | syndrome,( |
| R11 | T14 | T13 | arg2Of | SARS,( |
| R12 | T15 | T13 | arg3Of | ),( |
| R13 | T12 | T16 | arg1Of | syndrome,and |
| R14 | T20 | T16 | arg2Of | syndrome,and |
| R15 | T18 | T17 | arg1Of | East,Middle |
| R16 | T20 | T18 | arg1Of | syndrome,East |
| R17 | T20 | T19 | arg1Of | syndrome,respiratory |
| R18 | T20 | T21 | arg1Of | syndrome,( |
| R19 | T22 | T21 | arg2Of | MERS,( |
| R20 | T23 | T21 | arg3Of | ),( |
| R21 | T28 | T24 | arg1Of | are,coronaviruses |
| R22 | T24 | T25 | arg1Of | coronaviruses,( |
| R23 | T26 | T25 | arg2Of | CoVs,( |
| R24 | T27 | T25 | arg3Of | ),( |
| R25 | T16 | T28 | arg1Of | and,are |
| R26 | T30 | T28 | arg2Of | pathogens,are |
| R27 | T30 | T29 | arg1Of | pathogens,zoonotic |
| R28 | T30 | T31 | arg1Of | pathogens,with |
| R29 | T35 | T31 | arg2Of | and,with |
| R30 | T34 | T32 | arg1Of | rates,high |
| R31 | T34 | T33 | arg1Of | rates,fatality |
| R32 | T34 | T35 | arg1Of | rates,and |
| R33 | T37 | T35 | arg2Of | potential,and |
| R34 | T37 | T36 | arg1Of | potential,pandemic |
| R35 | T39 | T38 | arg1Of | development,Vaccine |
| R36 | T39 | T40 | arg1Of | development,focuses |
| R37 | T40 | T41 | arg1Of | focuses,on |
| R38 | T44 | T41 | arg2Of | target,on |
| R39 | T44 | T42 | arg1Of | target,the |
| R40 | T44 | T43 | arg1Of | target,principal |
| R41 | T44 | T45 | arg1Of | target,of |
| R42 | T50 | T45 | arg2Of | response,of |
| R43 | T50 | T46 | arg1Of | response,the |
| R44 | T50 | T47 | arg1Of | response,neutralizing |
| R45 | T50 | T48 | arg1Of | response,humoral |
| R46 | T50 | T49 | arg1Of | response,immune |
| R47 | T50 | T51 | arg1Of | response,"," |
| R48 | T57 | T51 | arg2Of | glycoprotein,"," |
| R49 | T57 | T52 | arg1Of | glycoprotein,the |
| R50 | T57 | T53 | arg1Of | glycoprotein,spike |
| R51 | T53 | T54 | arg1Of | spike,( |
| R52 | T55 | T54 | arg2Of | S,( |
| R53 | T56 | T54 | arg3Of | ),( |
LitCovid-sample-PD-FMA
| Id | Subject | Object | Predicate | Lexical cue | fma_id |
|---|---|---|---|---|---|
| T1 | 303-315 | Body_part | denotes | glycoprotein | http://purl.org/sig/ont/fma/fma62925 |
LitCovid-sample-CHEBI
| Id | Subject | Object | Predicate | Lexical cue | chebi_id |
|---|---|---|---|---|---|
| T1 | 303-315 | Chemical | denotes | glycoprotein | http://purl.obolibrary.org/obo/CHEBI_17089 |
LitCovid-sample-PD-NCBITaxon
| Id | Subject | Object | Predicate | Lexical cue | ncbi_taxonomy_id |
|---|---|---|---|---|---|
| T1 | 14-47 | Species | denotes | Severe acute respiratory syndrome | NCBItxid:694009 |
| T2 | 49-53 | Species | denotes | SARS | NCBItxid:694009 |
| T3 | 93-97 | Species | denotes | MERS | NCBItxid:1335626 |
LitCovid-sample-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T2 | 5-13 | Sentence | denotes | Abstract |
| T3 | 14-191 | Sentence | denotes | Severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) coronaviruses (CoVs) are zoonotic pathogens with high fatality rates and pandemic potential. |
| T4 | 192-316 | Sentence | denotes | Vaccine development focuses on the principal target of the neutralizing humoral immune response, the spike (S) glycoprotein. |
LitCovid-sample-PD-MONDO
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T1 | 14-47 | Disease | denotes | Severe acute respiratory syndrome | http://purl.obolibrary.org/obo/MONDO_0005091 |
| T2 | 49-53 | Disease | denotes | SARS | http://purl.obolibrary.org/obo/MONDO_0005091 |
LitCovid-sample-Pubtator
| Id | Subject | Object | Predicate | Lexical cue | pubann:denotes |
|---|---|---|---|---|---|
| 39 | 14-47 | Disease | denotes | Severe acute respiratory syndrome | MESH:D045169 |
| 40 | 49-53 | Disease | denotes | SARS | MESH:D045169 |
| 25 | 59-112 | Species | denotes | Middle East respiratory syndrome (MERS) coronaviruses | Tax:1335626 |
| 68 | 99-112 | Species | denotes | coronaviruses | Tax:11118 |
| 69 | 114-118 | Species | denotes | CoVs | Tax:11118 |
| 26 | 114-118 | Species | denotes | CoVs | Tax:11118 |
| 41 | 124-132 | Disease | denotes | zoonotic | MESH:D015047 |
| 33 | 293-298 | Gene | denotes | spike | Gene:43740568 |
| 27 | 317-328 | Species | denotes | Coronavirus | Tax:11118 |
LitCovid-sample-UniProt
| Id | Subject | Object | Predicate | Lexical cue | uniprot_id |
|---|---|---|---|---|---|
| T1 | 299-315 | Protein | denotes | (S) glycoprotein | https://www.uniprot.org/uniprot/Q9QAS2|https://www.uniprot.org/uniprot/Q9QAR5|https://www.uniprot.org/uniprot/Q9QAQ8|https://www.uniprot.org/uniprot/Q9IW04|https://www.uniprot.org/uniprot/Q9IKD1|https://www.uniprot.org/uniprot/Q990M4|https://www.uniprot.org/uniprot/Q990M3|https://www.uniprot.org/uniprot/Q990M2|https://www.uniprot.org/uniprot/Q990M1|https://www.uniprot.org/uniprot/Q91AV1|https://www.uniprot.org/uniprot/Q91A26|https://www.uniprot.org/uniprot/Q8V436|https://www.uniprot.org/uniprot/Q8JSP8|https://www.uniprot.org/uniprot/Q8BB25|https://www.uniprot.org/uniprot/Q86623|https://www.uniprot.org/uniprot/Q85088|https://www.uniprot.org/uniprot/Q85087|https://www.uniprot.org/uniprot/Q80BV6|https://www.uniprot.org/uniprot/Q7TFB1|https://www.uniprot.org/uniprot/Q7TFA2|https://www.uniprot.org/uniprot/Q7TA19|https://www.uniprot.org/uniprot/Q7T6T3|https://www.uniprot.org/uniprot/Q7T696|https://www.uniprot.org/uniprot/Q77NC4|https://www.uniprot.org/uniprot/Q6TNF9|https://www.uniprot.org/uniprot/Q6R1L7|https://www.uniprot.org/uniprot/Q6QU82|https://www.uniprot.org/uniprot/Q6Q1S2|https://www.uniprot.org/uniprot/Q696Q6|https://www.uniprot.org/uniprot/Q66291|https://www.uniprot.org/uniprot/Q66290|https://www.uniprot.org/uniprot/Q66199|https://www.uniprot.org/uniprot/Q66177|https://www.uniprot.org/uniprot/Q66176|https://www.uniprot.org/uniprot/Q66174|https://www.uniprot.org/uniprot/Q65984|https://www.uniprot.org/uniprot/Q5MQD0|https://www.uniprot.org/uniprot/Q5I5X9|https://www.uniprot.org/uniprot/Q5DIY0|https://www.uniprot.org/uniprot/Q5DIX9|https://www.uniprot.org/uniprot/Q5DIX8|https://www.uniprot.org/uniprot/Q5DIX7|https://www.uniprot.org/uniprot/Q52PA3|https://www.uniprot.org/uniprot/Q4U5G0|https://www.uniprot.org/uniprot/Q3T8J0|https://www.uniprot.org/uniprot/Q3LZX1|https://www.uniprot.org/uniprot/Q3I5J5|https://www.uniprot.org/uniprot/Q14EB0|https://www.uniprot.org/uniprot/Q0ZME7|https://www.uniprot.org/uniprot/Q0Q4F2|https://www.uniprot.org/uniprot/Q0Q475|https://www.uniprot.org/uniprot/Q0Q466|https://www.uniprot.org/uniprot/Q0GNB8|https://www.uniprot.org/uniprot/Q02385|https://www.uniprot.org/uniprot/Q02167|https://www.uniprot.org/uniprot/Q01977|https://www.uniprot.org/uniprot/Q008X4|https://www.uniprot.org/uniprot/P89344|https://www.uniprot.org/uniprot/P89343|https://www.uniprot.org/uniprot/P89342|https://www.uniprot.org/uniprot/P59594|https://www.uniprot.org/uniprot/P36334|https://www.uniprot.org/uniprot/P36300|https://www.uniprot.org/uniprot/P33470|https://www.uniprot.org/uniprot/P30208|https://www.uniprot.org/uniprot/P30207|https://www.uniprot.org/uniprot/P30206|https://www.uniprot.org/uniprot/P30019|https://www.uniprot.org/uniprot/P27655|https://www.uniprot.org/uniprot/P25194|https://www.uniprot.org/uniprot/P25193|https://www.uniprot.org/uniprot/P25192|https://www.uniprot.org/uniprot/P25191|https://www.uniprot.org/uniprot/P25190|https://www.uniprot.org/uniprot/P24413|https://www.uniprot.org/uniprot/P23052|https://www.uniprot.org/uniprot/P22432|https://www.uniprot.org/uniprot/P18450|https://www.uniprot.org/uniprot/P17662|https://www.uniprot.org/uniprot/P15777|https://www.uniprot.org/uniprot/P15423|https://www.uniprot.org/uniprot/P12722|https://www.uniprot.org/uniprot/P12651|https://www.uniprot.org/uniprot/P12650|https://www.uniprot.org/uniprot/P11225|https://www.uniprot.org/uniprot/P11224|https://www.uniprot.org/uniprot/P11223|https://www.uniprot.org/uniprot/P10033|https://www.uniprot.org/uniprot/P0DTC2|https://www.uniprot.org/uniprot/P07946|https://www.uniprot.org/uniprot/P05135|https://www.uniprot.org/uniprot/P05134|https://www.uniprot.org/uniprot/O90304|https://www.uniprot.org/uniprot/O39227|https://www.uniprot.org/uniprot/K9N5Q8|https://www.uniprot.org/uniprot/A3EXG6|https://www.uniprot.org/uniprot/A3EXD0|https://www.uniprot.org/uniprot/A3EX94|https://www.uniprot.org/uniprot/Q4ZJS1 |
LitCovid-sample-PD-GO-BP-0
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T2 | 264-287 | http://purl.obolibrary.org/obo/GO_0006959 | denotes | humoral immune response |
| T3 | 272-287 | http://purl.obolibrary.org/obo/GO_0006955 | denotes | immune response |
LitCovid-sample-GO-BP
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T2 | 264-287 | http://purl.obolibrary.org/obo/GO_0006959 | denotes | humoral immune response |
| T3 | 272-287 | http://purl.obolibrary.org/obo/GO_0006955 | denotes | immune response |
LitCovid-PD-GO-BP
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T2 | 264-287 | http://purl.obolibrary.org/obo/GO_0006959 | denotes | humoral immune response |
| T3 | 272-287 | http://purl.obolibrary.org/obo/GO_0006955 | denotes | immune response |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T2 | 5-13 | Sentence | denotes | Abstract |
| T3 | 14-191 | Sentence | denotes | Severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) coronaviruses (CoVs) are zoonotic pathogens with high fatality rates and pandemic potential. |
| T4 | 192-316 | Sentence | denotes | Vaccine development focuses on the principal target of the neutralizing humoral immune response, the spike (S) glycoprotein. |